NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

NCT03650894
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+, AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with TNBC must have tumors that are also AR+; Patients must be within 1 year following completion of curative-intent chemotherapy
Exclusions: Patients with active brain metastases or leptomeningeal metastases- see trial for details; Patients who have received more than 1 line of chemotherapy in the metastatic setting; Prior therapy with an anti-PD-1, -PD-L1, -PD-L, or- CTLA-4 agent or with bicalutamide, enzalutamide, or any other AR blocker
https://ClinicalTrials.gov/show/NCT03650894

Comments are closed.

Up ↑